Table 1.
Demographics Characteristics of the Analytic Sample (N = 159)
| Variable | Frequency (%) |
|---|---|
| Age at Baseline | |
| Median (Range) | 55 (22–87) |
| Sex | |
| Male | 97 (61%) |
| Female | 62 (39%) |
| Treatment | |
| Intervention | 86 (54%) |
| Control | 73 (46%) |
| Race | |
| Caucasian | 134 (84%) |
| Asian | 3 (2%) |
| Native Hawaiian or other Pacific Islander | 0 |
| African American | 4 (3%) |
| American Indian/Native Alaskan | 1 (1%) |
| More than one race | 2 (1%) |
| Missing | 15 (9%) |
| Working Status | |
| Working | 104 (65%) |
| Not working | 41 (26%) |
| Missing | 14 (9%) |
| Clinical Service | |
| Medical Oncology | 140 (88%) |
| Radiation Oncology | 19 (12%) |
| Cancer Diagnosis | |
| Breast | 29 (18%) |
| Colorectal | 28 (17%) |
| Prostate | 25 (16%) |
| Head and Neck | 19 (12%) |
| Testicular | 14 (9%) |
| Bladder | 12 (8%) |
| Esophageal | 10 (6%) |
| Gastric | 7 (4%) |
| Other Gastrointestinal Cancers | 6 (4%) |
| Miscellaneous | 5 (3%) |
| Unknown Primary | 3 (2%) |
| Sarcoma | 1 (1%) |
| Stage | |
| I | 20 (13%) |
| II | 31 (20%) |
| III | 45 (28%) |
| IV | 58 (36%) |
| Missing | 5 (3%) |
| Chemotherapy Type at Timepoint 2 | |
| Taxane Only | 67 (42%) |
| Platinum Only | 78 (49%) |
| Platinum and Taxane | 14 (9%) |
| Neurotoxic Chemotherapy Duration at Timepoint 2 | |
| Received less than 1/3 of planned treatment | 73 (46%) |
| Received at least 1/3 of planned treatment | 46 (29%) |
| Received at least 2/3 of planned treatment | 31 (19%) |
| Completed treatment | 9 (6%) |
| Cumulative M2 Dose Category at Timepoint 2a | |
| Low Risk | 119 (75%) |
| Moderate Risk | 35 (22%) |
| High Risk | 5 (3%) |
| Pain Medications Receiving at Timepoint 2 | |
| Opioid(s) alone | 21 (13%) |
| Gabapentin alone | 2 (1%) |
| Acetaminophen and/or Non-Steroidal Anti-inflammatory drugs | 2 (1%) |
| Calcium/Magnesium | 1 (1%) |
| Gabapentin + Vitamin B6 | 1 (1%) |
| Pregabalin + Opioid | 1 (1%) |
| Tegretol + Opioid | 1 (1%) |
| None | 130 (81%) |
| Previous Neurotoxic Chemotherapy Receipt | |
| Yes | 8 (5%) |
| No | 151 (95%) |
| Comorbid Conditions that Increase Chemotherapy-Induced Peripheral Neuropathy Risk | |
| Multiple | 7 (4%) |
| Diabetes | 6 (4%) |
| High Body Mass Index | 5 (3%) |
| Baseline Neuropathy | 4 (3%) |
| Chronic Pain | 2 (1%) |
| None | 135 (85%) |
| Concurrent Severe Cancer Treatment Symptoms | |
| Yes | 43 (27%) |
| No or Unknown | 116 (73%) |
| QLQ-CIPN20b Sensory (n = 158) at Timepoint 2 | |
| Mean (SD, Range) | 7.11 (10.01,0–62.96) |
| QLQ-CIPN20b Motor (n = 158) at Timepoint 2 | |
| Mean (SD, Range) | 6.09 (10.65,0–71.43) |
a
For participants receiving multiple neurotoxic chemotherapy agents, dose category was determined based on the highest dose one of the specific agents they were receiving. Cumulative neurotoxic dose categories were constructed based upon published literature [37–40].
b
European Organisation for Research and Treatment of Cancer Quality of Life Chemotherapy-Induced Peripheral Neuropathy 20